Moreover, Sox2 enhances the chemoresistance of CSCs to cisplatin, possibly by inhibiting ABCG2 expression and resistance to oxidative stress in CD44+ CD271+ CSCs in HNSCC[109]. Here, CD44 is linked to head and neck squamous cell carcinoma.